Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

MicroRNA and Protein expression

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Cell signaling
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

To determine differences in microRNAs and proteins in healthy patients, patients with MCI, and patients with AD. Patients' blood samples will be tested by chip to test microRNA expression and liquid chromatography-mass spectrometry to determine protein expression. Changes in microRNAs and proteins will be correlated with the changes of cognition. This information will be used to construct a kit that can contain probes to detect a few microRNAs or proteins.

Target Population/ Population Being Studied

Normal control people, patients with mild cognitive impairment (MCI) and patients with Alzheimer's disease (AD)

Length of Current Trial
1.5 years
Number of Trial Participants

120

Estimated Trial Completion
March 2020
What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure mRNA (e.g.,qPCR)

Sponsor

Sun Yat-sen University

“Protein and microRNA Markers for Early Detection of Alzheimer's Disease.” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT03388242?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=4&rank=36